Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any guess as to developments on N.Y.C proposal?
only partial filled running away .0098
lol mistake .009
anyone getting filled .095?
added more
Just checked the 200 day we could kick it back from .08
How low will it go before supported .09? Imo .09-.11 range
Electronic Device
[0081] The aforedescribed crucible can be used in the fabrication process involving BMG. Because of the superior properties of BMG, BMG can be made into structural components in a variety of devices and parts. One such type of device is an electronic device.
[0082] An electronic device herein can refer to any electronic device known in the art. For example, it can be a telephone, such as a cell phone, and a land-line phone, or any communication device, such as a smart phone, including, for example an iPhone.TM., and an electronic email sending/receiving device. It can be a part of a display, such as a digital display, a TV monitor, an electronic-book reader, a portable web-browser (e.g., iPad.TM.), and a computer monitor. It can also be an entertainment device, including a portable DVD player, conventional DVD player, Blue-Ray disk player, video game console, music player, such as a portable music player (e.g., iPod.TM.), etc. It can also be a part of a device that provides control, such as controlling the streaming of images, videos, sounds (e.g., Apple TV.TM.), or it can be a remote control for an electronic device. It can be a part of a computer or its accessories, such as the hard drive tower housing or casing, laptop housing, laptop keyboard, laptop track pad, desktop keyboard, mouse, and speaker. The article can also be applied to a device such as a watch or a clock.
my money my loss i'll take the risk/ reward on bmsn i've been here awhile loading up August 2014 was cited in the report for ind i'll wait thanks.
from Regen papers . "In the case of dCellVax we are blocking immune suppressive genes to induce immune stimulation, whereas in this case, we silenced immune stimulatory genes to block only the part of the immune system that is responsible for rejection of heart transplants."
What the price tag for D cell vax worth?
Share
Tools
Comment
Print
Contact Author
Reprint
Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis ($NVS) worth up to $680 million.
D Cell Vax is vastly superior Quark's RNAi treatment misses the mark in a Phase II kidney trial
July 29, 2014 | By Damian Garde
Share
Tools
Comment
Print
Contact Author
Reprint
Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis ($NVS) worth up to $680 million.
The treatment, QPI-1002, is a small interfering RNA (siRNA) designed to shut off the p53 gene in kidney transplant patients, thereby protecting tissues from damage caused by a disorder called delayed graft function. Quark mounted a 331-patient Phase II trial in hopes the treatment could meet its primary endpoint of a 30% relative risk reduction compared to placebo, but QPI-1002 came through at just 15.1%, missing its main goal.
Quark was quick to point out that its drug crossed the 30% threshold in a few patient subgroups, and the biotech noted that safety signals were similar between the trial's treatment and placebo arms. QPI-1002's benefits were particularly pronounced in patients whose kidney donors were older than 45, Quark said, and the company believes the results merit further study.
IBM SmarterCommerce Webinar: File Synch / File Share for the Enterprise – Taken to the Extreme
Join this webinar with Derek Brink, Vice President and Research Fellow for IT Security and IT GRC at the Aberdeen Group, to discover how to develop your own innovative approach to managed file transfer. Find out how to bring new levels of efficiency, visibility and collaboration to every process – and reach new heights of success for your business. Click here to watch this on-demand webinar today! .
Sign up for our FREE newsletter for more news like this sent to your inbox!
But whether there's a Phase III effort in store remains up in the air.
Back in 2010, Novartis stepped in and paid $10 million up front for an option to license QPI-1002, promising to hand over up to $670 million more in fees and milestones if the gene-silencing treatment met its standards for success. Flunking a primary endpoint in Phase II would seem like a deal-breaker, but Novartis hasn't provided an update on the outstanding deal and didn't respond to a request for comment on Tuesday.
Novartis has already curtailed much of its internal RNAi research efforts, telling FierceBiotech in April that that decision stemmed from "ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow."
As for Quark, while its upbeat announcement is littered with recommendations for additional studies of QPI-1002, the company has made no mention of a planned Phase III, and, like Novartis, it didn't respond to emailed questions on the matter.
Beyond QPI-1002, Quark's clinical siRNA pipeline includes the Pfizer ($PFE)-partnered PF-655, in midstage development for diabetic macular edema and wet age-related macular degeneration, and QPI-1007, a wholly owned treatment for optic neuropathy and glaucoma.
"Although Regen's focus with Dr. Min is the development of technology licensed from Benitec BioPharma to stimulate the immune system, in the form of dCellVax, the current publication illustrates the broad applicability of gene silencing technology, not only for immune stimulation, but also for targeted immune suppression," said Dr. Thomas Ichim, Chief Scientific Officer of Regen BioPharma. "In the case of dCellVax we are blocking immune suppressive genes to induce immune stimulation, whereas in this case, we silenced immune stimulatory genes to block only the part of the immune system that is responsible for rejection of heart transplants."
Organ transplants are the only available cure for end stage organ failure conditions such as heart, liver, and kidney failure. Although conventional immune suppressants are effective at blocking initial rejection of the transplanted organ, chronic usage of immune suppressants is associated with increased infections and incidence of cancer. This is because current drugs to treat transplant rejection globally suppress the immune system, making the body more susceptible to pathogens and cancer. In contrast, the approach described in the current publication selectively blocks the immune system from killing the transplanted heart, while allowing other components of the immune system to function normally.
"The current publication is an example of how work performed at Regen in the development of dCellVax has applications outside of its original intended field of use. Through our ongoing collaborative efforts we plan to not only accelerate the development of dCellVax in the area of breast cancer, but also to advance the field of gene silencing, which may have benefits in a wide variety of medical conditions," said David Koos, Chairman and CEO of Regen BioPharma Inc.
Currently Regen BioPharma is progressing in its IND enabling experiments for dCellVax, with anticipation of filing an IND in August 2014.
wise my friend
i was in at .06 and added just took some off the table
great ride guys i'll be back let it cool
One day someone will look back on this technology and say wish I knew that was the game changer in solar tech 20/20 is always in hind sight. "Our mandate was to create a solar cell that would produce substantially more power than the current technology at a low enough cost of production to deliver a considerably lower cost per watt of solar electricity.
No Pump Just the facts""Our technology team has worked very hard on this product," said Jim Nelson, CEO of Solar3D. "Two powerful characteristics of our 3D Solar Cell make it superior to current technology. First, it is substantially more efficient in producing power. Second, is our wide-angle light collection feature, which allows our 3D Solar Cell to collect light at all times of the day, month and year, an attribute unique in the solar world. Our early computer simulation analysis indicated that the combination of these two features would produce double the power of a conventional solar cell. Our early indication is that we will be able to meet that ambitious goal. This device could be a giant leap forward, allowing solar power to achieve grid parity."
got filled loaded up trying to sell some other holdings.
gives me another opportunity to buy that 300k shares lower thanks
Tesla??????One Partner?????Mr. Nelson concluded, "We anticipate combining the last steps with one partner who will be able to produce a manufacturing prototype, do a test run, and go commercial. This approach will simplify the development process considerably. Finding the right partner is our goal. We are currently holding conversations with several potential partners, including large domestic and international manufacturers."
I recall paying Over $5,000.00 for a pentium 3 computer back in the days.
Today's i phone is much much better cost less. yes if apple were to raise it's price people will be fighting over it.
I'm sure apple could pay the price Lqmt is not cheap so is apple that's why everyone always wants the best things in life and it's not cheap.
Not Production LQMT the company announced the availability of a turnkey injection molding solution from Engel, its 3rd Generation Liquidmetal Molding System. This machine will serve as an integral component of the licensing business model, as it can be readily delivered to any licensor around the world. An added benefit of this model is that not only does Liquidmetal capture a license fee from its partner, but it also receives a portion of the net $ sales of the Engel machine.
One of the Machine will be available onsite at the Tech Center soon to be announce as stated for customer to have hands on demo.
The current industrial video compression standard H.264/AVC was adopted
in 2003. It provides a superior video compression eciency compared to other
existing and widely spread standards such as MPEG2 or VP8. However the
amount of video data stored on local devices or transmitted over the networks
is permanently increased. According to Cisco [2] mobile video trac was 51
percent of the entire global Internet trac by the end of 2012 and it is ex-
pected to be 66 percent by 2017. The ability to get better compression rates
will eventually decrease network bandwidth load.
The emerging of a more ecient next generation video coding standard is
of a high demand at the moment. There seem to be two main contenders for
the position of the next state-of-the-art video compression standard: JCT-VC
H.265/HEVC and Google VP9.
VIDG Is the undiscovered stock that Wall Street Missed.!!!!
http://www.cnet.com/news/google-urges-fast-adoption-of-vp9-video-compression/
"If you adopt VP9, as you can very quickly, you'll have tremendous advantages over anyone else out there using H.264 or VP8, (its predecessor)," said VP9 engineer Ronald Bultje in a talk here at Google's developer conference. "You can save about 50 percent of bandwidth by encoding your video with VP9 vs. H.264." ..... That's huge folks....
Effective August 15, 2013 the Company entered into and closed an asset purchase agreement acquiring the right, title and interest to 27 Vid3G mobile application patents from Leexoo Technology Ltd/Vid3G LLC (“VID3G”), a LLC formed in the state of Nevada. As consideration for the purchase, the Company issued 60,000,000 shares of common stock to VID3G, which is valued at $1,000,000 based on the discounted closing trading price of the Company’s common shares on August 15, 2013.
5) Financial Statements
The issuer has filed its Quarterly Financials for the Nine Months Ended March 31, 2014 on the OTC Disclosure and News Service - see Quarterly Report – VID3G FS Q3 MAR 2014.
6) Describe the Issuer’s Business, Products and Services
A. a description of the issuer’s business operations;
Mobile Application Software Development
The Company has transitioned into a technology development company, specializing in working with under-performing companies and bringing together the resources needed for them to attain financial stability and growth.
Our focus is on companies showing a positive upside while striving to bring new technologies and unique products to market.
Effective August 15, 2013 the Company entered into the business of mobile application software development with the acquisition of the right, title and interest to 27 Vid3G mobile application patents from Leexoo Technology Ltd/Vid3G LLC (“VID3G”), a LLC formed in the state of Nevada.
Through the acquisition of the Leexoo technologies and Vid3G LLC technologies, the Company is currently developing the next generation social video sharing mobile application for Asia and North America.
VIDG pre market trading $$$$$$$
LQMT Moving higher on pre market that's a good sign$$$$$
Can Liquidmetal® alloys be used without restrictions?
No, Liquidmetal® Technologies Inc. already has long-term contractual commitments for consumer electronics and watch parts.
This relationship with Lqmt and Mc Gill is they are building Out The Tech Center with LQMT...That's huge (IMO)
http://www.mcgillcorp.com/public/index.php
Just curious Bones why did you get in on Lqmt
Thomas Steipp
We have one scheduled for arrival, early in the summer for our technology development centre. To be clear, again, we're going to continue to use contract manufacturers for the bulk of our manufacturing, as Visser is doing today.
That sounds to me The center aqnd the engel's machine is sooon!
Early summer we into July 10th
Licensing our technology to partners in vertical markets, such as medical, aerospace and sporting goods applications, promises to be of increasing importance to the Company going forward. The readiness of the Liquidmetal injection molding machine, which will be sold and supported by Engel, is an important step forward in our licensing strategy," saidTom Steipp, Liquidmetal Technologies' CEO.
"Collaboration between both companies has been ongoing for several years. Joint advancements with Liquidmetal's induction melt system and Engel's injection molding machinery have led to a process capable technology platform. Engel Machinery, in conjunction with Liquidmetal Technologies, looks forward to bringing this exciting economical technology to market," said Mark Sankovitch, president, Engel North America.
Liquidmetal Technologies is the leading developer of amorphous alloys, which are distinguished by their ability to retain a random structure when they solidify, in contrast to the crystalline atomic structure that forms in ordinary metals and alloys.
Engel has eight production plants in Europe, North America and Asia (China and Korea), as well as subsidiaries and representatives in over 85 countries.
,
Related Articles
Engel commits to Liquidmetal process development
Liquidmetal targets injection molded medical applications
Significant progress reported as liquid metal molding scales up
Liquidmetal injection molding: Is it disruptive or just a disruption?
Progress From A year ago http://www.plasticstoday.com/blogs/liquidmetal-injection-molding-it-disruptive-or-just-disruption05312013
Hang on for the opening of the Tech Center and Engel's Machine.
And, four, open a world-class technology development centre in Rancho Santa Margarita, where customers and licensees can view firsthand, how Liquidmetal can provide innovative solutions.
We are all excited about the - launching these new initiatives and look forward to giving you an update on our progress during the next call.
We Need an Update$$$$$$$$$$$$$$
Throughout the course of this year, you will see us increase our investments in marketing and sales to
1) one, established Liquidmetal as a leading authority and centre of collaborative development on all aspects of Liquidmetal Technology.
2)Two, to increase the size and expertise of our sales rep organizations, to include enhanced training and support activities.
3)Three, expand innovative marketing activities, which communicate the capabilities and benefits of Liquidmetal as a disruptive force in certain applications, complementing MIM and other metal working technologies.
4)And, four, open a world-class technology development centre in Rancho Santa Margarita, where customers and licensees can view firsthand, how Liquidmetal can provide innovative solutions.
Unidentified Analyst
And maybe just one last question on the, the new ENGEL machine, is that still scheduled to be showing up here in end of June this year?
Thomas Steipp
We have one scheduled for arrival, early in the summer for our technology development centre. To be clear, again, we're going to continue to use contract manufacturers for the bulk of our manufacturing, as Visser is doing today.
But we have determined that, we know a lot about it here, we developed most of the advanced technologies and capabilities and having a centre where people can come in, watch their parts being prototyped and see the latest from us.
It's really essential in our overall ability to sell and close the business. So, we're excited about opening that up in a not too distant future.
When?
Liquidmetal Technologies' (LQMT) CEO Tom Steipp on Q1 2014 Results - Earnings Call Transcript
SA Transcripts, Recent earnings call transcripts (24,781 clicks)
We cover over 5K calls/quarter
Profile| Send Message|
Get real-time alerts (2,108 followers)
Liquidmetal Technologies' (LQMT) CEO Tom Steipp on Q1 2014 Results - Earnings Call Transcript
May. 9, 2014 5:17 PM ET | 7 comments | About: Liquidmetal Technologies, Inc. (LQMT)
Executives
Tom Steipp - President and CEO
Tony Chung - CFO
Paul Hauck - Vice President of Worldwide Sales and Support
Analysts
Liquidmetal Technologies, Inc. (OTCQB:LQMT) Q1 2014 Results Earnings Conference Call May 8, 2014 4:30 PM ET
Operator
Good afternoon. Welcome to the Liquidmetal Technologies' First Quarter Fiscal 2014 Conference Call. My name is Kevin, and I will be your conference operator this afternoon.
Joining us on today's call are Liquidmetal's President and CEO, Tom Steipp; CFO, Tony Chung and our special guest Paul Hauck, our recently hired Vice President of Worldwide Sales. Following their remarks, we will open up the call for your questions.
Before we proceed, I would like to provide the company's Safe Harbor statement with important questions regarding forward-looking statements made during this call as follows. All statements made by management during this call that are not based on historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended.
Such forward-looking statements include, but are not limited to those made by Mr. Steipp and Mr. Chung regarding the company's cash revenue outlook and technology development.
While management has based any forward-looking statements made during the call on its current expectations, the information on which such expectations were based may change.
These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside the company's control that could cause actual results to materially differ from such statements.
Such risks, uncertainties and other factors include, but are not necessarily limited to those set forth under risk factors in the company's Annual Report on Form 10-K for the year ended December 31, 2013.
Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. The company disclaims any intention and undertakes no obligation to update or revise any forward-looking statements.
You are also urged to carefully review and consider the various disclosures in the company's Annual Report on Form 10-K for the year ended December 31, 2013, as well as other public filings with the SEC since such date.
I would also like to remind everyone that this call will be available for replay, starting later this evening via a link available in the Investor Relations section of the company's website at www.liquidmetal.com.
Now, I would like to turn the call over to the company's President and CEO, Mr. Tom Steipp.
Thomas Steipp
Thank you, Kevin. Welcome everyone. Thank you for joining us on today's call. The first quarter of fiscal 2014 turned out to be significant in the overall evolution of Liquidmetal. Here is a recap of the results and advancements that occurred during the first quarter leading up to this call.
Revenue for the first quarter was $160,000 versus $122,000 for the first quarter of 2013. The arbitration with VPC continues to progress with the hearing now scheduled for August 2014. We continue to focus on outcomes that will be in the best interest of our shareholders and customers.
We successful raised $11.5 million to-date under our equity line of credit to fund continuing operations including the expansion of our marketing and sales activities.
As our summary for first quarter and preview for the fiscal year 2014, I'd like to recap our strategic goals and tactical activities.
Since beginning the exclusive licensing arrangement - signing the exclusive licensing arrangement with Apple, in August of 2010, we streamlined the organization and focused our efforts on building out the significant IP intellectual property portfolio around a scalable commercialized echo system, the zirconium based alloys and metal molding machines.
Our current IP portfolio has increased to 63 issuing patterns and 56 additional pattern pending filed.
As the technology began to stabilize, we shifted our efforts to building out a partnership network that was capable of making the very significant investments, necessary to bring this technology to commercial availability on a global basis.
At the same time we began the very major process of moving the manufacturing capability out of our facility in Rancho Santa Margarita to remote location with our contract manufacturer, Visser Precision Cast in Denver Colorado proving that the technology was stable enough to have a third party with close collaboration and full access to our technology, manufactured Liquidmetal parts successfully.
This complete process accommodated in the fourth quarter of 2013 and the first quarter of 2014 with the full commercial availability of two alloys for Materion and a state-of-the-art metal molding machine from ENGEL.
To be clear, our focus as an organization is to be a catalyst for changing the way that people think about how they develop small complex parts. Our role in that is to be the process development experts.
Defining, refining and expending the alloys manufacturing systems and application components to allow our customers and licensees to use Liquidmetal Technology to its fullest potential.
This entails a careful integration of marketing, sales, engineering and manufacturing functions into unified program to serve customers, licensees and partners.
During this past quarter we took an important step forward by hiring Paul Hauck as our Worldwide Vice President of Sales and Support. Paul brings a 30 year track record of significant achievement within the Metal Injection Molding industry which went from three revenue to over $2 billion during that spend.
Here is what you will see from us during the coming year. An increase in marketing activities builds around applications. A revamping of our web coverage to expand the numbers and focus on those who have proven success in MIM and other complimentary metal working technology.
The establishment of our Liquidmetal Technology Development Center in Rancho Santa Margarita to include state-of-the-art manufacturing which will allow us to showcase the technology with perspective customers and licenses.
And finally an expansion of our licensing efforts to leverage our Liquidmetal Technology echo system which is ready enable to be deployed worldwide.
Apple is said to be interested in Liquidmetal's alloys for touch tensors and home buttons.
Seems that the case buttons and clasps are made of a material that something LQMT has (IMO)
is LQMT materials used in this concept iwatch?
http://www.macrumors.com/2014/07/02/2-5-inch-iwatch-concept/
Pure speculation but stands to reason Silevo target for cell is 24 %
sltd's cell is rated as tested and being developed as we speak in final stage
" Our 3D solar cell is calculated to have an internal efficiency of 25.47%, more than any existing silicon solar cell, and is designed to take advantage of low cost manufacturing processes. "
"High Efficiency Solar cell efficiency is the measure of how much incident sunlight is converted into electricity. Most solar cells today are made from silicon, an inexpensive and abundant raw material. Due to the physics of silicon, the theoretical maximum efficiency of high-grade crystalline silicon solar cells is approximately 29%. In commercial practice, the efficiency ranges from 15% to 19%.(1)
Elon is a very smart guy and does his home work It's stands to reason SLTD's cell must be in his cross hairs at this efficiency rate
http://grist.org/news/now-elon-musk-wants-to-revolutionize-solar-panel-production/?utm_source=newsletter&utm_medium=email&utm_term=Daily%2520June%252018&utm_campaign=daily
excellent progress from report and the potential implications are huge....
CONCLUSION:
This study demonstrates that the simultaneous silencing of CD40 and CD80 genes has synergistic effects in preventing allograft rejection, and may therefore have therapeutic potential in clinical transplantation.